Clinical Trials Logo

HER2-positive Breast Cancer clinical trials

View clinical trials related to HER2-positive Breast Cancer.

Filter by:

NCT ID: NCT00006228 Completed - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Start date: July 2000
Phase: Phase 2
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill breast cancer cells. Phase II trial to study the effectiveness of trastuzumab plus interleukin-2 in treating patients who have metastatic breast cancer that has not responded to previous trastuzumab therapy.

NCT ID: NCT00003440 Completed - Clinical trials for HER2-positive Breast Cancer

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

Start date: July 1998
Phase: Phase 3
Study type: Interventional

This randomized phase III studies how well two different regimens of paclitaxel with or without trastuzumab works in treating patients with or without HER-2/Neu breast cancer that is inoperable, recurrent, or metastatic. Drugs used in chemotherapy, such as paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known what regimen of paclitaxel is more effective with or without trastuzumab in treating patients with breast cancer.